Related Experiment Video
Updated: Jun 7, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Clinical study on the using methods of cisplatin in lung cancer chemotherapy]
1The Department of Medical Oncology, Cancer Center, The First University Hospital, West China University of Medical Sciences, Chengdu, Sichuan 610041, P.R.China.
Background:
To compare the therapeutic effectiveness and toxicity between 1-day perfusion and 3-day perfusion of high-dose cisplatin combined chemotherapy for lung cancer.
Methods:
Sixty-four cases of pathologically proved lung cancer were randomized into groups A and B. Group A (32 cases) received cisplatin at d1, and group B (32 cases) received cisplatin at d1-3. Total dosages of cisplatin were same for both groups (100 mg/m²).
Results:
Delayed vomiting in group B (40.63%) was significantly lower than that of group A (53.13%) (P<0.05); the early nephrotoxicity rate of group B(25.00%) was lower than that of group A (46.88%), but there was no statistically significant difference between two groups (P>0.05). The therapeutical response was 62.50% in group A, and 68.75% in group B. No significant difference of the chemotherapeutical response was observed between the two groups (P>0.05).
Conclusions:
In the combined chemotherapy of lung cancer, the division administration of high-dose cisplatin can not only guarantee the therapeutic response, but also abate the gastrotoxicity and the nephrotoxicity of cisplatin.
